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were excluded. For this study, pts were randomly assigned either to a model deriva- 
tion(n=750) or validation(n=751) group. Logistic regression was used to identify those 
patient characteristics that best predicted P-blocker utilization in the derivation group. 
Modal goodness-of-fit was assessed. and the model validated. 
Results: The mean age of the population was 67215 yrs, 55% were women, 25% were 
African American and 69% had coronary altery disease. Assessment of left ventricular 
funcbon(LVF) was documented in 90% of pts. ACE-I therapy was prescribed in 76% and 
P-blockers were prescribed in 50% overall and in 59% of pts with systolic HF. In the deri- 
vation model, characteristics associated with receiving P_blockers included documented 
LVF(p<O.Ol). systolic dysfunction(pcO.Ol), coronary artery disease(p<O.Ol), inSurance 
type(p<O.Ol), and hypertenslon(p=03). Trends were noted for younger age(pc0.01) and 
ACE-I therapy(p=O.Ol), In the final multivariate model, coronary artery disease, docu- 
mented LVF, hypertension, and insurance type were significant predictors of P-blocker 
therapy Area under the ROC curve for both the final model and the derwation sample 
was 0.67. 
Conclusions: Although not optimal, eblocker utilization in patients with HF is higher 
than previously reported. Important predictors of eblocker prescription I” this sample of 
managed care pts are documented LV function and coronary artery disease. Strategies 
to increase &blocker therapy should be developed. 
long-term reductions an LV volumes, in contrast to ongoing ACE-I alone. Despite a 
change in therapy, C patients did not experience more adverse events and a similar 
number of patients completed the study. Therefore, Carvedilol might be regarded as pos- 
sible alternative to ACE-I in mild CHF patients. 
1184-74 Effects of Intravenous Nesiritide on Coronary 
Vasomotor Regulation and Myocardial Oxygen 
Extraction 
Andrew D. Michaela Andrew Klein, Kanu Chatterjee, University of California, San 
Francisco, San Francisco, CA 
1184-72 Mortality and Morbidity in Men, Women, and 
Postmenopausal Women in Val-HeFT 
Silia K. Maiahalme, Lawrence Baruch, Nora Aknay, Liselotte GoedsCMeinen, Monika 
Hofmann. Nancy Feliciano, Tampere University Hospital, Tampere, Finland 
Background: The Influence of gender on treatment and suwival in congestive heart fall- 
ore (HF) is understudied. Here, post-hoc analyses of primary endpoints of mortality (M) 
and combined mortality/morbidity and secondary endpoint of non-fatal morbidity (NFM) 
examined differences in men. women and postmenopausal women (age _> 55years) in 
the Valsartan Hear? Failure Trial (Val-HeFT). Methods: 5010 HF patients (4007 men and 
1003 women) were randomized to either valsartan (V) or placebo (P) in addition to pre- 
scribed HF therapy. Outcomes in pooled populations (V+P) and treatment effects (V vs 
P) were evaluated using Cox regression analysis. 
Results: Regardless of subgrouping by age above or below 55, the pooled population of 
women had lower M than men (16.3% vs 20.4%, p=O.O02) but women. especially post- 
menopausal women (n=791) had higher NFM (subgroup: Z55years - 21.1% vs 17.4%, 
p=O.O35). However, women with coronary heart disease, regardless of age above or 
below 55, had similar M as men (20.5% vs 22.6%, ~~0.187) while the higher rate of NFM 
remained (24.5% vs 16.3%, p<O.OOl). Similar results were seen wth diabetes co-mor- 
bidity. The use of background therapy wth ACE inhibitors, digoxin, O-blockers and diuret- 
ICS was similar between women and men, and none of these therapies had an Impact on 
gender differences within the pooled population. Between-treatment analyses for V vs P 
within males, females and post-menopausal females demonstrated a favorable effect or 
trend on combined mortality/morbidity endpoint in all three subgroups. 
Background: Nesiritide (Natreco@ Scios Inc., Sunnyvale, CA) is a recombinant form of 
human B-type natriuretic peptide, that has been shown to be beneficial in patients with 
decompensated congestive heart failure. This study evaluated the effects of nesiritide on 
coronary blood flow (CBF) and myocardial oxygen extraction. 
Methods: Patients referred for cardiac catheterization were enrolled. Patients who had 
baseline SBP < 95 mm Hg, were on vasopressors. and had received nitroglycerin or cal- 
cium blockers within the previous 24 hours were excluded. After diagnostic catheteriza- 
tion and full heparinization, a O.OlCinch Doppler FloWire was positioned in the proximal 
portion of an unobstructed coronary artery to measure average peak velocity (APV). 
Right heart catheterization and simultaneous blood gas sampling from the coronary sinus 
and aorta were performed at baseline and after a 30.min IV infusion of nesiritide (2mcg/ 
kg bolus and 0.01mcgikglmin). Quantitative coronary angiography was performed at 
baseline, lBmin, and 30-min. CBF=(coronary altery area)(APV)(0.3). Coronary resis- 
tance=mean arterial pressure/CBF. 
Results: Ten patients were enrolled. The mean age was 56*12 years (range 43-60). 
Three were female. Mean left ventricular ejection fraction was 46+20% (range 20.70%). 
During nesiritide infusion, pulmonary capillary wedge pressure decreased 46% 
(p=O.O02). mean pulmonary artery pressure decreased 19% (p=O.O3). systemic vascular 
resistance decreased 6% (p&22), and mean arterial pressure decreased 11% 
(p=O.O07). There was no significant change in cardiac output. Coronary artery APV 
increased from 21+6 cm/s at baseltne to 24i7 cm/s at 5 min (p=O.Ol), returning to base- 
line at 15 and 30 minutes. Coronary artery diameter increased 15% at 15. and 30.min 
(p=O.O07). CBF increased 33% at 15 min (p=O.O3) and 32% at 30 min (p=O.O7). Coronary 
resistance decreased 29% at 15 min (p=O.O2) and 29% at 30 min (p=O.O4). Myocardial 
oxygen extraction decreased 5% at 30 min (p=O.13). 
Conclusion: Nesiritide exerts coronary vasodilator effects, in both the epicardial conduc- 
tance and resistance arteries. There is a trend toward decreased myocardial oxygen 
extraction during nesiritide infusion. 
1184-75 Effect of Nonsurgical Heart Failure Therapies on 
Functional Mitral Regurgitation: A Meta-Analysis 
Conclusions: In Val-HeFT. the female gender was associated with lower M but a higher 
rate of NFM, especially for postmenopausal women. Primary HF etiology of coronary 
heart disease or a history of diabetes dilutes the gender benefit for M independent of 
age. These findings suggest that serious attention should be paid to postmenopausal 
women and those with comorbidities. Future studies should continue to enroll more 
female patients. Gender differences in HF M and NFM must be seriously considered both 
I” clinical practice and in the design of future HF studies. 
Madhavi Kadivala Martin Fewerman. Jason M. Lazar, Winthrop-University Hospital, 
Mineola, NY 
Background: Functional mitral regurgitation (MR) is a common echocardiographic find- 
ing in patients with congestive heart failure (CHF) and its presence and magnitude are 
associated with an adverse prognosis. The objective of this systematic overview using 
meta-analysis was to assess effects of hearl failure therapies on functional MR. 
Methods: Studies ware retrieved using medline and ovid (key words: mitral regurgitation, 
heart failure treatment). All clinical trials published I” English from 1965 to the present 
date ware included. Eighteen previously published studies met the criterion for our analy- 
sis. In these studies Doppler echocardiography was used to assess the degree of MR 
before and at least 1 month after the initiation of ace inhibitors (ace-l), beta-blockers (bb) 
or pacing in patients with CHF. Standardized effect size of reduction in MR was calcu- 
lated using Cohen’s ‘d’ for each study. Random effects model was used for the meta- 
analysis. Pearson’s correlation analysis was performed to assess the relation between 
various echo parameters and MR. 
Results: Functional MR was assessed in a total of 594 patients in 18 trials (4 ace-l, 4 bb 
and 10 pacing). By unweighted analysis, ace-l reduced MR by 59i 20% With the major- 
ity of patients on background ace-l therapy. bb reduced MR by 55i 24%. Pacing reduced 
MR by 26+ 15%, when added to optimal medical therapy. In a random effects model, the 
effect size (d) of MR reduction by ace-l and bb was large, d = - 1.04+ 0.36 (95% Cl - 
1.75, -0.34) and -i.l& 0.36 (95% Cl -1.86;0.46) respectively. Pacing therapy had a 
moderate effect on reduction of MR ( d= -0.59+ 0.06 (95% Cl -0.76, -0.43)). Pearson’s 
correlation analysis of effect sizes showed a trend toward reduction in MR correlating 
with an improvemerit in LV ejection fraction (r= -0.38, p ~0.15) and decrease in LV end 
diastolic diameter (r= 0.46, p= 0.11). 
Conclusion: In petlents with CHF and functional MR, ace-l and bb reduce MR to a large 
extent. Pacmg including cardiac resynchronization therapy reduced MR to a moderate 
extent. Further studies are required to understand the mechanism of these therapies on 
MR. 
1184-73 Replacement of Angiotensin Converting Enzyme 
Inhibition by Carvedilol Results in Long-Term Reversed 
Left Ventricular Remodeling in Mild Heart Failure and Is 
Well Tolerated: Results of the CARMEN (Carvedilol Ace- 
inhibitor Remodeling in Mild heart failure EvaluatioN) 
Study 
Willem J. Remme, Jordi Soler-Soler, Lars Ryden, Per Hildebrandt. Marco Bobbio, 
Wvbren Jaarsma, Michel Komaida, Armin Scherhaa. Guenther Rieaaer, on behalf of the 
&MEN investigators, Sticaras, Rotterdam, The Netherlands -_ 
Background: In chronic heart failure (CHF), the effect of Pblockade on mortality. mor- 
bidity and cardtac remodeling have always been evaluated in addition to ACE-I. It is 
unknown whether the combination is mandatory or whether in terms of remodeling ACE- 
I can successfully be replaced by eblockade. CARMEN compared the effect on remod- 
eling of the ACE-I Enalapr~l (E) against Carvedilol (C), a combined pl .@2 -blocker with 
additional al-receptor blockade and anti-oxidant properties. 
Methods: A parallel-group, 3.arm. double-dummy, multi-center study was conducted in 
13 European countries. Patients ware randomized to C &E. C and E treatment, uptitrated 
on C to 25mg BID target dose and/or E to 1Omg BID target dose, and continued for 16 
months. Earlier ACE-I and P-blocking treatment was stopped prior to randomization. In 
the C&E arm, C was uptitrated first. Effects of left ventricular (LV) remodeling were 
assessed by transthoracic echocardiography (biplane) at baseline. months 6, 12 and 16 
at a central core laboratory 
Results: 572 mild CHF patients, mean age 62 years, 61% males, were randomized. Of 
these, 65% (N=374) had been on ACE-I treatment prior to the study start, whereas only 
6% were on p-blockade. A subgroup analysis of the primary endpoint in former ACE-I 
users showed that LV end-systolic volume index was reduced at month 16 by 4.7 ml& 
(p=O.O06) I” the C group (n=l03) and by 6.0 ml/m2 (p=O.OOi) in the C&E group (n=ll4) 
from baseline. In contrast, in the E group (n=lOl) it increased by 0.6 ml/m2 (ns). The 
overall safety and tolerability profiles were comparable. In groups C&E, C and E adverse 
events occurred in 76%,75% and 74 %, respectively, whereas similar percentages of 
patients completed treatment (74%,70% and 72% respectively). 
Conclusion: Combination therapy (C&E) gave best results. However, replacement of 
ACE-I with C also resulted in significant reversal of cardiac remodeling with sustained, 
1184-76 Do Statins Provide Clinical Benefit in High-Risk 
Coronary Artery Disease Patients With Advanced Left 
Ventricular Dysfunction? 
Sandra P. Revna Benjamin D. Home, Robert R. Pearson, Tami L. Bair, Chloe A. Allen 
Maycock, Kismet D. Rasmussen, Jill Hall, Stephanie V. Moore, Jeffrey L. Anderson, 
Joseph B. Muhlestein, Dale G. Renlund, LDS Hospital, Salt Lake City, UT, University of 
Utah, Salt Lake City, UT 
Background: HMG-CoA reductase inhibitors (statins) are one of the most potent modifi- 
ers of coronary artery disease (CAD) natural history. PrescrIption rates and efficacy of 
statins have not been explicitly studied in patients (pts) with left ventricular dysfunction 
(LVD. Ejection Fraction [EFr40%). Potentially, statins could adversely effect LVD pts 
due to decreased hepatic blood flow or pharmacologic interaction (e.g with amiodarone). 
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Further, lipid lowering may not be as beneficial in advanced disease. We compared sur- 
vival associated with statin therapy in CAD pts with and without LVD. 
Methods: A cohort of 2,202 non-LVD pts and 364 LVD pts with angiographically defined 
CAD (270% stenosis), were studied from the registry of the Intermountain Heart Collab- 
orative Study at LDS Hospital. Risk factors and clinical data, including statin prescription 
at discharge, were recorded at baseline. Pts were followed for 3.0+1.9 years (maximum 
7.7 years) to determine the incidence of mortality. Cox regression and Kaplan-Meier esti- 
mates were used to model survival in both groups. 
Results: Patient age (63+12 years) and gender (34% female) did not differ between the 
groups. Statins were prescribed at discharge for 28% of non-LVD and 26% of LVD pts 
(p=NS). Among non-LVD patients, mortality was 6.6% for statin prescribed pts and 
12.7% for those not prescribed statins (p=O.O05 by log-rank); among LVD pts, mortality 
was 16.0% when prescribed statins and 32.6% when no statin was prescribed (p=O.O17 
by log-rank). After adjustment for covariables. these associations remained for non-LVD 
pts (hazard ratio [HR]= 0.66,95% Cl= 0.47-0.93), and LVD pts (HiX0.57, Cl= 0.33-0.99). 
No interaction was found between statin prescription and EF for moriality (p-interac- 
tiow0.71). 
Conclusion: Proportionate benefit from statin prescription was similar in LVD and non- 
LVD groups, but absolute benefit was greater in LVD pts (16% vs. 6% absolute mortality 
reduction). These results demonstrate the benefit of statin discharge prescription, 
regardless of degree of LVD and emphasize current underutilization, particularly in those 
with LVD. 
before 12h 24h lweek 
SBP(mmHg) 92*13 96+12’ 95*16 96+14 
Cl (Vmin/mz) i.7ko.3 2.4+0.4’ 2.5+0.6 2.5*0.6’ 
PCWP (mmHg) 26+6 25+6 23+6’ 22*10’ 
RA (mmHg) 15t6 11*5’ 1 O-t6* 1 Ok6 
SVR (IU Wood) 19a7 14*5’ 14*4 14*5 
-p&u5 versus basellne 
Conclusion: The addition of levosimendan had a sustained-therapeutic effect in clini- 
cally unstable patients with CHF refractory to continuous dobutamine and furosemide 
infusions. This regimen could be used as a bridge to left ventricular assist device implan- 
tation or heart transplantation. 
1184-79 Acute Intravenous Ranolazine Improves Lefl Ventricular 
Function in Dogs With Heart Failure: A Dose Escalation 
Study 
Hideaki Morita, George Suzuki, Margaret P. Chandler, William C. Stanley, Brent K. 
Blackbum. Hani N. Sabbah, Henry Ford Health System, Detroit, MI. Case Western 
Reserve University, Cleveland, OH 
Background: To explore the use of intravenous (iv) ranolazine. a partial fatty acid oxida- 
tion inhibitor, as acute therapy for heart failure (HF), we determined the effects of up-titra- 
tion and reversibility of ranolazine in 6 dogs with microembolizations-induced HF. 
Methods: Ranolazine was given as 0.05 mg/kg bolus followed by iv infusion at 0.1, 0.3, 
1.0 and 3.0 mgkglhr each for 1 hour. Heart rate (HR), peak left ventricular (LV) systolic 
pressure (LVSP). stroke volume (SV), LV end-diastolic volume (EDV), LV end-systolic 
volume (ESV). LV ejection fraction (EF) and ranolazine plasma concentration (RANc) 
were measured at baseline and at the end of each dose. Results: The results are shown 
in the table. Ranolazine decreased ESV without affecting EDV. thus increasing EF at all 
doses in a dose and RANc deoendent manner. The increase in EF olateaued at doses 
X.3 mgikglhr, suggesting a half maximal response at -0.1 mg/kg/hr at RANc of 67+11 
no/ml. Ranolazine had nominal effects to reduce HR at doses >0.3 ma/ka/hr and LVSP at 
March 19,2003 
1184-77 Utilization of ACE-I and B-blocker Therapy in Managed 
Care Patients With Heart Failure: NC ACE Project 
David C. Gaff. Carfa A. Sueta, David W. Brown, Jill McArdle, Sharon Peacock, Alain 
Bertoni, Wake Forest University School of Medicine, Winston-Salem, NC, Medical 
Review of North Carolina, Gary, NC 
Background: Heart failure (HF) results in substantial morbidity and mortality in the US. 
Despite evidence-based guidelines recommending proven therapies, translation into clin- 
ical practice is suboptimal. The goal of the North Carolina Achieving Cardiac Excellence 
(NC ACE) Project is to increase the utilization of angiotensin converting enzyme inhibitor 
(ACE-l) and @blocker therapies in patients with HF. The purpose of this study is to com- 
pare the management of Medicare and Medicaid patients with HF enrolled in managed 
care. 
Methods: Data were abstracted from outpatient medical records for 971 Medicare (3 
managed care plans) and 654 Medicaid (2 plans) patients treated for HF during 2000. 
Patients receiving dialysis were excluded. 
Results: Compared to Medicaid patients, Medicare patients were older (76i3 vs. 59*14 
years), more likely to be white (64 vs. 47%), and men (50 vs. 30%). More than 80% of 
Medicare (n=795) and Medicaid (n=526) patients had documentation of a quantitative or 
qualitative assessment of left ventricular function (LVF). Left ventricular systolic dysfunc- 
tion (LVSD) was present in 37% (n=297) of Medicare patients and 37% (n=197) of Med- 
icaid patients. 
Indicator Medicare Medicaid 
LVF Assessment 849 (67%) 573 (63%) 
ACE-I in LVSD 215 (72%) 147 (75%) 
ACE-l Intolerance 42 (14%) 23 (12%) 
bblocker in LVSD 144 (46%) 96 (43%) 
eblocker Intolerance 34 (12%) 25 (13%) 
Conclusion: Assessment and treatment of HF appears similar in Medicare and Medicaid 
managed care patients. Although not optimal, these rates are substantially higher than 
previously reported. Opportunities for increasing appropriate use of &blockers should be 
prioritized in these populations. 
1184-78 Hemodynamic Effects of Levosimendan in Addition to 
Dobutamine Infusion in Patients With Advanced Heart 
Failure Intractable to Dobutamine Infusion Alone 
Panaqiotis Pavazoqlou, Maria Anastasiou-Nana, Eleftheria Tsagalou, John Terrovitis. 
Elias Tsolakis. Argirios Dalianis, George Alexopoulos. John Kanakakis, Konstantinos 
Chrfstodoulou, John N. Nanas, University of Athens, Athens, Greece 
Background: Levosimendan is a new calcium-sensitizing agent with positive inotropic 
and vasodilatory effects. 
Purpose: This study measured the magnitude and duration of the hemodynamic 
response to an infusion of levosimendan In clinically unstable patients with advanced 
congestive heart failure (CHF) pretreated with dobutamine and furosemide. 
Methods: In thirteen patients with advanced CHF. 48-77 years of age, in NYHA func- 
tional class IV, previously treated with intermittent dobutamine infusions, and hospital- 
ized for clinical instability despite continuous dobutamine. lOpg/kg/min. and furosemide, 
10 mglh, infuslons, a continuous infusion of levosimendan, in a bolus of 6 kgikg, followed 
by a 0.2 W/kg/min infusion for 24 h. was added. The patients were followed for 7 days, 
including serial right-heart catheterizations. The effect on Systolic Blood Pressure (SBP), 
Cardiac Index (Cl), Pulmonary Capillary Wedge Pressure (PCWP), Right Atrial Pressure 
(RA) and Systemic Vascular Resistance (SVR), before and at 12 hours, 24 hours and 1 
week after levosimendan administration, was recorded. 
Results: The results are summarized in the Table 
I  _  
a dose of 3.0 mglkglhr. The effect of ranolazine (0.05 mglkg bolus + 0.3 mg/kg/hr for 1 
hr) declined after stopping infusion in proportion to RANc. Conclusions: Intravenous 
ranolazine improves LV function in dogs with chronic HF in a reversible, dose and con- 
centration dependent manner with little or no impact on HR and LVSP. 
RanolazineDose (mglkglhr) 
Baseline 0.1 0.3 1 .o 3.0 
HR (beats/min) 83+4 80_+6 75_+5’ 74+5 73 i 5’A 
LVSP (mmHg) 9623 102~4 9723 9423 89 _+4’” 
SV (ml) 19+1 23_+1’ 25_+1’” 2621.” 26_+1’” 
EDV (ml) 6624 6623 6524 66+3 6524 
ESV (ml) 4724 43_+4* 41_+3’” 39+3^” 3923’” 
EF (%) 30~2 36_+2’ 36 22’” 33 + 3’” 33 -+ 3.” 
RANc (ng/ml) 0 67i4 106+94 557 i a7 1259_+1354 
*=PcO.O5 vs. Baseline; “=PcO.O5vs. 0.1 mglkglhr 
1184-80 Effect of the Angiotensin Converting Enzyme Inhibitor 
Trandolapril on Functional Status and Furosemide 
Consumption in Patients With Reduced Left Ventricular 
Function After Myocardial Infarction 
Jawdat Abdulla, Lars Kober, Christian Tarp-Pedersen, Gentofte University Hospital of 
Copenhagen, Copenhagen, Denmark 
Background: lnformatlon on the direct benefit of angiotensin converting enzyme inhibi- 
tors on symptoms are scarce and in contrast to the overwhelming amount of information 
on survival. Effect of the use of concommitant diuretic therapy on symptoms has been 
also questioned. Therefore we studied development of New York Heart Association 
(NYHA) classification and use of furosemide in the Trandolapril Cardiac Evaluation Study 
(TRACE). 
Methods: In TRACE 1749 consecutive patients with left ventricular systokc dysfunction 
after myocardial infarction (MI) were randomized to either placebo or trandolapril. The 
patients were assessed for changes in NYHA classes and use of furosemide every 3 
months and were followed up 2-4 years. 
Results: There were no differences in baseline characteristics between the two treatment 
groups. The majority of the patients were in NYHA classes II and I. Both placebo and 
trandolapril groups showed equal improvement in NYHA classes without any significant 
differences (P> 0.05, figure). This result was also found in patients with NYHA class II or 
greater at the time of randomization. Trandolapril resulted in a mild but significant reduc- 
tion of the use of furosemide with a mean reduction of 12 mg/day overall during follow up 
(pcO.001, figure). 
Conclusion: Despite a significant reduction in mortality, trandolapril did not improve 
